---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-23-000010"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:58:39.133560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q4 revenue up 6.2% constant currency; adjusted EPS $0.81

## Summary
- Q4 revenue $274.9M (+6.2% constant currency); GAAP EPS $0.03, adjusted EPS $0.81.
- FY2022 revenue $1.02B (+2.9% constant currency); GAAP loss per share $1.61, adjusted EPS $2.39.
- First clinical cases of Essenz perfusion system completed; LifeSPARC ECMO 510(k) cleared.
- FDA Warning Letter for Munich facility and 3T Heater-Cooler closed out.

## SEC filing metadata
- accession: 0001639691-23-000010
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/livn-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-23-000010
- JSON: https://secwatch.observer/filing/0001639691-23-000010.json
- Plain text: https://secwatch.observer/filing/0001639691-23-000010.txt

## Key facts
- Earnings Releases
  LivaNova PLC updated its FY2023 guidance (initiated).
  - Period: FY2023
  - Guidance: initiated
  - Result: guidance update
  source text: LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm
- Earnings Releases
  LivaNova PLC reported Q4 2022 results: revenue $274.9 million, EPS $0.03.
  - Period: Q4 2022
  - Revenue: $274.9 million
  - EPS: $0.03
  - Result: reported results
  source text: Fourth-quarter revenue of $274.9 million increased 1.8 percent on a reported basis and 6.2 percent on a constant-currency basis, as compared to the prior-year period • Fourth-quarter U.S. GAAP diluted earnings per share was $0.03 and adjusted diluted earnings per share was $0.81
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm
- Earnings Releases
  LivaNova PLC reported FY2022 results: revenue $1.02 billion, EPS $1.61.
  - Period: FY2022
  - Revenue: $1.02 billion
  - EPS: $1.61
  - Result: reported results
  source text: Full-year 2022 revenue of $1.02 billion decreased 1.3 percent on a reported basis and increased 2.9 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 revenue, excluding revenue from the Heart Valve business which was divested effective June 1, 2021, increased 2.3 percent on a reported basis and 6.7 percent on a constant-currency basis, as compared to the prior year • Full-year 2022 U.S. GAAP diluted loss per share was $1.61 and adjusted diluted earnings per share was $2.39
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000010/0001639691-23-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.